These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 33243092)

  • 1. Effect of
    Adegbola AJ; Soyinka JO; Bolaji OO
    Pharmacogenomics; 2020 Dec; 21(18):1289-1297. PubMed ID: 33243092
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.
    Adegbola AJ; Rana A; Adeagbo BA; Bolarinwa RA; Olagunju AE; Siccardi M; Owen A; Bolaji OO
    Pharmacogenet Genomics; 2020 Jul; 30(5):96-106. PubMed ID: 32209837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy and
    Mutagonda RF; Minzi OMS; Massawe SN; Asghar M; Färnert A; Kamuhabwa AAR; Aklillu E
    Drug Metab Dispos; 2019 Dec; 47(12):1415-1424. PubMed ID: 31744845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.
    Mutagonda RF; Kamuhabwa AAR; Minzi OMS; Massawe SN; Asghar M; Homann MV; Färnert A; Aklillu E
    Malar J; 2017 Jul; 16(1):267. PubMed ID: 28673292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
    Abdullahi ST; Olagunju A; Soyinka JO; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Owen A; Khoo S
    Br J Clin Pharmacol; 2019 Mar; 85(3):540-550. PubMed ID: 30471138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection.
    Adegbola A; Abutaima R; Olagunju A; Ijarotimi O; Siccardi M; Owen A; Soyinka J; Bolaji O
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers.
    Abdullahi ST; Soyinka JO; Olagunju A; Bolarinwa RA; Olarewaju OJ; Bakare-Odunola MT; Winterberg M; Tarning J; Owen A; Khoo S
    J Clin Pharmacol; 2020 Mar; 60(3):351-360. PubMed ID: 31549442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
    Francis J; Barnes KI; Workman L; Kredo T; Vestergaard LS; Hoglund RM; Byakika-Kibwika P; Lamorde M; Walimbwa SI; Chijioke-Nwauche I; Sutherland CJ; Merry C; Scarsi KK; Nyagonde N; Lemnge MM; Khoo SH; Bygbjerg IC; Parikh S; Aweeka FT; Tarning J; Denti P
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria.
    Lohy Das J; Rulisa S; de Vries PJ; Mens PF; Kaligirwa N; Agaba S; Tarning J; Karlsson MO; Dorlo TPC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Okaba-Kayom V; Mayanja-Kizza H; Katabira E; Hanpithakpong W; Pakker N; Dorlo TP; Tarning J; Lindegardh N; de Vries PJ; Back D; Khoo S; Merry C
    J Antimicrob Chemother; 2012 May; 67(5):1217-23. PubMed ID: 22316571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
    Usman SO; Oreagba IA; Akinyede AA; Agbaje EO; Akinleye MO; Onwujuobi AG; Ken-Owotor C; Adeuja O; Ogunfowokan T; Kogbe S; Owolabi ET; Adeniji H; Busari AW; Hassan OO; Abideen G; Akanmu AS
    J Pharmacol Sci; 2020 Nov; 144(3):95-101. PubMed ID: 32921396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic properties of the antimalarial combination therapy artemether-lumefantrine in normal-weight, overweight and obese healthy male adults.
    Sugiarto SR; Page-Sharp M; Drinkwater JJ; Davis WA; Salman S; Davis TME
    Int J Antimicrob Agents; 2022 Jan; 59(1):106482. PubMed ID: 34818520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania.
    Kilonzi M; Minzi O; Mutagonda R; Baraka V; Sasi P; Aklillu E; Kamuhabwa A
    Malar J; 2020 Feb; 19(1):66. PubMed ID: 32046718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria.
    Usman SO; Oreagba IA; Kadri MR; Adewumi OO; Akinyede A; Agbaje EO; Abideen G; Busari AA; Hassan OO; Akinleye MO; Akanmu AS
    Eur J Clin Pharmacol; 2021 Sep; 77(9):1341-1348. PubMed ID: 33755736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome.
    Kiaco K; Rodrigues AS; do Rosário V; Gil JP; Lopes D
    Malar J; 2017 Sep; 16(1):383. PubMed ID: 28934955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa.
    Onyamboko MA; Hoglund RM; Lee SJ; Kabedi C; Kayembe D; Badjanga BB; Turner GDH; Jackson NV; Tarning J; McGready R; Nosten F; White NJ; Day NPJ; Fanello C
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
    German P; Parikh S; Lawrence J; Dorsey G; Rosenthal PJ; Havlir D; Charlebois E; Hanpithakpong W; Lindegardh N; Aweeka FT
    J Acquir Immune Defic Syndr; 2009 Aug; 51(4):424-9. PubMed ID: 19506482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.